Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that longer treatment durations and the launch of novel treatments will grow the drug market for chronic myelogenous leukemia almost 12% annually between 2004 and 2009. Novel agents such as those from Bristol-Myers Squibb and Novartis will increase patient drug consumption by offering a viable, and likely durable, second-line pharmacological approach to the treatment of chronic myelogenous leukemia.

The new Pharmacor study entitled Chronic Myelogenous Leukemia also found that elderly patients with poor prognosis are most likely to be deemed ineligible for treatment with imatinib therapy.

"In most markets, elderly patients with poor prognosis are deemed ineligible for imatinib therapy because of the high cost of this treatment. Instead, these patients are treated with less expensive drugs, such as hydroxyurea," said Jude Nelson, analyst at Decision Resources, Inc. "Another factor related to the use of imatinib is the prescription of inappropriately low doses in an effort to mitigate cost and toxicity by some clinicians practicing outside of academic centers. Oncologists and hematologists working in private practice and in smaller hospitals need to be educated concerning the dangers of selecting for imatinib-resistant clones."

About Chronic Myelogenous Leukemia

Chronic myelogenous leukemia is a form of chronic leukemia characterized by increased production of myeloid cells in the bone marrow. It was traditionally treated with chemotherapy, interferon, and bone marrow transplantation, although Novartis's Gleevec/Glivec (imatinib mesylate) has radically changed management of the disease. With the advent of Gleevec/Glivec, the disease has become easy to treat, and the vast majority of patients opt for this well-tolerated oral therapy.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

New England States Form Strategies to Control Drug Costs

View Now